The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation and pharmacokinetic (PK) evaluation of an oral AKT inhibitor, LY2503029 (LY).
S. A. Limentani
Research Funding - Lilly
H. Burris
Research Funding - Lilly
A. P. Anderson
Research Funding - Lilly
L. H. Brail
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
D. Satonin
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
I. Gueorguieva
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
S. Jones
No relevant relationships to disclose
J. R. Infante
No relevant relationships to disclose
J. C. Bendell
No relevant relationships to disclose